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AbsTrACT
Patients with primary biliary cholangitis (PBC) can be 
stratified into low-risk and high-risk groups based on their 
response to treatment. Newly published guidelines from 
the British Society of Gastroenterology suggest low-risk 
patients can be managed substantially in primary care. 
This represents a shift from existing practice and makes 
assumptions about service capacity and the willingness 
of both patients and health care practitioners (HCPs) to 
make this change. The aim of this paper is to identify 
possible barriers to the implementation of these new care 
pathways through review of the PBC-specific literature 
and by identifying the experiences of patients and HCPs 
managing a different condition with comparable patients 
and disease characteristics. Searches of MEDLINE, CINAHL 
and EMBASE were undertaken. Within the existing PBC 
literature there is little data surrounding stakeholder 
perspectives on place of care. Review of the breast cancer 
literature highlights a number of barriers to change 
including primary care practitioner knowledge and work 
load, communication between healthcare settings, and the 
significance of the established doctor–patient relationship. 
Further research is needed to establish the extent to which 
these barriers may surface when changing PBC care 
pathways, and the actions required to overcome them.
IntroductIon
Primary biliary cholangitis (PBC), formerly 
known as primary biliary cirrhosis, is a 
chronic autoimmune liver disease. The inci-
dence of PBC in the UK is 32.2 per 100 000,1 
with approximately 20 000 people presently 
affected. Incidence is higher in females 
compared with males (10:1) and in the fifth 
and sixth decade of life such that a woman 
over 40 years of age has a 1/1000 chance of 
having this condition.2 While early natural 
history studies suggested that life expec-
tancy from time of diagnosis was less than 
10 years,3 this is no longer true. Increasing 
understanding of the pathophysiology of the 
disease, along with the ability to diagnose 
PBC earlier in its course, and the widespread 
use of ursodeoxycholic acid (UDCA) has led 
to the recognition that, for many patients, 
PBC is a chronic disease but not life limiting. 
The name changes from ‘primary biliary 
cirrhosis’ to ‘primary biliary cholangitis’ was 
adopted into use by clinicians, researchers 
and patients in 2015 to reflect the emerging 
evidence that only a minority of patients go 
on to develop cirrhosis and end-stage liver 
failure.
Patients with PBC can be categorised or 
‘stratified’ into two groups (responders or 
non-responders) based on whether or not 
there is an improvement in biochemical 
parameters following 12 months of treat-
ment with UDCA. Those who respond to 
treatment with UDCA (between 60% and 
70% of all patients) do not go on to develop 
progressive disease and have a transplant free 
survival similar to the general population.4–7 
Up until a few years ago, in the absence of 
second line treatment, those who failed to 
respond to UDCA were at risk of progres-
sion to end stage liver disease and liver trans-
plantation, with younger patients and males 
with PBC over-represented in this group.8 
However, following recent positive outcomes 
in trials, obeticholic acid (OCA), a Farsenoid 
X receptor agonist has been approved by the 
National Institute for Health and Care Excel-
lence (NICE) for the treatment of patients 
who have had an inadequate response to 
treatment with UDCA or were unable to 
tolerate UDCA.9 However, despite the avail-
ability of effective treatment, there is no 
cure for the disease and even for those who 
respond, life-long treatment with UDCA is 
still required and patients will requirement 
regular follow-up.
Reflecting both the increased under-
standing of the natural history of PBC and the 
availability of second line therapy, recently 
published guidelines from the British Society 
of Gastroenterology10 highlight the impor-
tance of formal risk stratification for all 
patients at 1-year postdiagnosis with manage-
ment of treatment non-response or high-risk 
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Figure 1 Study selection process for primary biliary cholangitis.
patients necessitating discussion with specialist services 
for consideration of OCA or clinical trials. For those with 
low-risk disease, while long-term treatment and follow-up 
are required, it has been suggested that this does not 
necessarily need to take place in a hospital-based setting 
and there is the opportunity for an increased role for 
primary care services in the long-term care of these 
patients. These recommendations are echoed in the 
recent guidelines from the European Association for the 
Study of Liver Disease.11
New models of care for management of chronic liver 
disease as a whole are essential and timely. In contrast to 
other countries in Western Europe, rates of liver disease 
are increasing in the UK; over 600 000 people are known 
to have liver disease with 10% of these having cirrhosis 
and liver disease mortality has increased by 400% over the 
last 40 years.12 The Lancet Commission on Liver Disease 
has highlighted the numerous challenges currently faced 
by the National Health Service (NHS) and by patients 
including inequalities in service provision (the so-called 
‘postcode lottery’). The Commission’s recommendations 
included the need to improve access to specialist care 
and services for those most in need as well as increasing 
involvement from primary care and community services.12
However, changing patterns of established care 
requires ‘buy in’ from all users of the pathways: patients, 
stakeholders, and health care practitioners (HCPs) in 
primary, secondary and tertiary settings. This requires an 
appreciation of the various user’s perspectives of current 
care, of the possible impacts any changes will have on 
them as new pathways are introduced, and in turn the 
identification of potential barriers to change and the 
facilitators required for these to be overcome. This paper 
seeks to identify what is already known about these factors 
in the currently available PBC literature. In addition, we 
also review the existing literature around patient and 
HCP perspectives on follow-up in a comparable condi-
tion where recent changes in management parallel the 
proposed evolution of PBC in order to gain insights that 
may be relevant to reforms in PBC care.
Methods
review of the PBc literature
A scoping review was chosen with the goal of estab-
lishing the type and breadth of literature available.13 The 
potential remained to perform a systematic review if the 
scoping study revealed a large body of relevant literature. 
Using the framework set out by Arksey and O’Malley,14 
the following stages were undertaken: (1) identification 
of the research question, (2) identification of relevant 
studies, (3) selection of studies, (4) charting of the data 
(5) collation, summarising and reporting of results.
The research question was divided into two parts. 
(1) What is the breadth and type of literature available 
looking at the perspectives of patients and clinicians 
on all aspects of PBC and its management? (2) Is there 
existing data looking specifically at how patients and 
clinicians view the role of primary care in the manage-
ment of PBC?
A search of three electronic databases: MEDLINE, 
CINAHL and EMBASE was carried out. A schematic 
of the study selection process is shown in figure 1. 
The following search terms were used: Primary biliary 
cirrhosis OR primary biliary cholangitis AND quality 
OR experience OR perception* OR perspective* OR 
attitude* OR expectation* OR understand* OR view*. 
Eleven hundred and fifty-one distinct citations were iden-
tified by the initial database searches with 24 included 
in the final analysis. In order to establish whether there 
were any additional resources available but not captured 
by the initial electronic database searches, a review of all 
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the reference lists from the 24 texts was undertaken; this 
yielded one further article. A search of the grey litera-
ture using Open Grey (http://www. opengrey. eu) using 
the search terms ‘primary biliary cirrhosis’ and ‘primary 
biliary cholangitis’ returned 18 and five citations, respec-
tively. None were relevant to the research question. The 
key characteristics and emerging research themes of the 
25 studies are summarised in table 1.
choosing a comparable condition
A number of factors were deemed to be of relevance when 
selecting a comparable condition including the demo-
graphics of the patient population, availability of clear 
stratification parameters and the need for ongoing but 
minimal input long-term follow-up for low-risk groups. 
Possible conditions considered included other forms of 
liver disease, other chronic diseases (including autoim-
mune and non-autoimmune) and malignancies. Breast 
cancer satisfied the criteria (see table 2); it is mainly a 
disease of older females, patients are stratified after 
primary treatment into those who have achieved remis-
sion and those who have not responded, and even where 
remission has been achieved, there continues to be a need 
for a form of life-long input for responders that does not 
necessarily require specialist input.15 A number of other 
parallels are also evident, including the ongoing psycho-
logical morbidity, and symptoms that may persist despite 
remission being achieved. In addition, issues around how 
best to follow-up patients who have undergone curative 
treatment remain a source of debate.16 NICE guidelines 
on breast cancer from 2002 stated that all patients should 
be followed up for a minimum of 3 years (although 
they did not state how frequently patients should be 
seen) before care could be transferred back to primary 
care.17 A systematic review of the breast cancer literature 
in 200718 identified seven randomised controlled trials 
which compared different forms of follow-up care both 
in terms of frequency of review and appropriate health-
care professional. Overall, they found no difference in 
recurrence rates, survival or quality of life. The updated 
NICE guidelines in 200919 reflect the existing research 
and recommend patients decide how they would like to 
be followed up after primary treatment is completed with 
options including primary care, secondary care or shared 
care.
review of the breast cancer literature
The second scoping exercise again followed the Arksey 
and O’Malley structure.14 As the topic of long-term 
follow-up in breast cancer survivorship has been widely 
studied, the goal of this review was to (1) gain an overview 
of the commonly occurring themes in this literature and 
(2) identify barriers to follow-up in primary care which 
may have potential relevance in PBC. An electronic data-
base search was undertaken using the same three data-
bases. A schematic of the sample selection process is 
shown in figure 2. The following search terms were used: 
breast cancer OR breast carcinoma OR breast neoplasm 
AND perspective* OR opinion* OR view* OR attitude* 
OR experience* or perception* AND discharge OR 
‘follow-up’ OR ‘primary care’ OR ‘secondary care’ OR 
hospital* OR special* OR general practice*. A date limit 
was set to cover 1996–2016 in order to capture data rele-
vant to recent changes in breast cancer follow-up strategies 
between the 2002 and 2009 NICE guidelines and studies 
undertaken following this change in practice. Review of 
the reference lists from relevant articles did not identify 
any further relevant citations within the specified date 
range. For each study the following data were extracted: 
authorship, publication date, location, population type, 
sample size and barriers to primary care follow-up.
results
PBc literature
Twenty-five studies identified from the PBC literature 
were included in the final analysis (table 1). Seventeen 
quantitative studies were identified,20–36 four qualita-
tive,37–40 two mixed methods study,41 42 one literature 
review43 and one patient narrative.44 Of these studies, 24 
focused on the patient perspective only, with one looking 
at both patient and physician perspectives.31 The majority 
of the studies focused on symptoms and quality of life. 
Of those that took a qualitative or mixed approach, one 
study looked specifically at the impact of fatigue,37 one at 
the experience of receiving a diagnosis40 and the other at 
stigma associated with PBC.42 Two studies explored the 
experience of living with PBC.39 41
While no studies directly addressed issues surrounding 
follow-up care and the role of primary, secondary and 
tertiary care, there were a number of emerging themes 
that are likely to be of relevance when looking at the 
impact of changes in the structure of care. Montali et 
al39 identified the theme of ‘delegitimisation’ and how, 
when patients look well (as is often the case in PBC), the 
impact of their disease is minimised by familial and social 
contacts. Discharge from specialist care to the primary 
care setting may further impact these perceptions both 
for the patient and their social contacts. The significance 
of the disease may be perceived as lesser when care is 
transferred to practitioners who may be seen as being less 
‘specialist’ or ‘expert’.40 44 In addition, the stigma experi-
enced by patients may also be influenced by new changes 
in care structure. A study looking at posts on an internet 
forum for patients with PBC revealed that a number of 
posts were related to stigma38 and when directly asked 
many patients reported that they felt a degree of stigma 
associated with their disease.42 This stigma seemed to 
stem not specifically from the diagnosis of PBC itself but 
with the associations between liver disease and cirrhosis 
with drugs and alcohol. Of note, this stigma was not 
just related to the perception of lay people but also to 
non-specialist HCPs.
Breast cancer literature
From the breast cancer literature, 14 papers were 
included in the final analysis (table 3). Quantitative 
copyright.
 o
n
 18 July 2019 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2018-000226 on 17 June 2019. Downloaded from 
4 Corrigan M, et al. BMJ Open Gastro 2019;6:e000226. doi:10.1136/bmjgast-2018-000226
Open access 
Table 1 Summary of research themes in PBC addressing patient and physician perspectives on disease
Authorship
Publication 
date Location Methodology
Population (size of 
sample with PBC) Research question
Blackburn et al 20 2007 UK Quantitative Patients (n=24) Are patients with fatigue more psychologically 
impaired than those without fatigue and is there a 
role for CBT?
Dyson et al 21 2016 UK Quantitative Patients (n=2055) Impact of age at presentation on quality of life and 
the role of symptomatology
Fahey 43 1999 UK Literature review Patients Experience of women living with PBC and how 
understanding this may improve nursing care
Gross et al 22 1999 USA Quantitative Patients post liver 
transplant (n=157, 
42% PBC)
Quality of life post-transplant
Comparison between PBC and PSC patients
Relationship between quality of life and clinical 
factors
Hale et al 44 2012 UK Patient narrative Patients (n=1) Experience of living with fatigue
Huet et al 23 2000 Canada Quantitative Patients (n=116)
Healthy controls
Validation of the fatigue impact score in a large 
patient cohort
Link between fatigue and mental health status
Relationship between psychosocial and physical 
factors
Ismond et al
*conference 
abstract only41
2018 Canada Mixed methods 
(quantitative 
with post hoc 
qualitative 
analysis
Patients
(n=119)
Experience of living with PBC
Impact on daily life and relationships
Jorgensen 37 2006 USA Qualitative Patients (n=8) Experience of living with fatigue
Lasker et al 38 2005 USA Qualitative Patients (n=275) Why do patients use internet resources?
Does disease stage affect disease experience?
What are the similarities between issues 
experiences by patients with PBC and those with 
other chronic disease?
Lasker et al 24 2010 USA Quantitative Patients on waiting 
list or post-transplant 
(n=100)
Uncertainty and how it relates to quality of life 
scores
Mells et al 25 2013 UK Quantitative Patients (n=2402) Quality of life scores and the role of fatigue, 
depression, sleep, social and cognitive function
Miura et al
*conference 
abstract only26
2016 Japan Quantitative Patients (n=217) Symptom profile and impact on quality of life
Montali et al 39 2011 Italy Qualitative Patients (n=23) Illness experience of women with PBC, sick role 
and relationship with others
Navasa et al 27 1996 Spain Quantitative Patients post liver 
transplant (n=29)
Quality of life scores, complications and use of 
medical services post-transplant
Pearce et al 40 2011 UK Qualitative Patients (n=28+) Experience of receiving a diagnosis of PBC
Use of this information to develop resources for 
patients at diagnosis
Poupon et al 28 2004 France Quantitative Patients (n=276) Comparison of quality of life scores among patients 
compared with healthy controls
Relationship between clinical parameters and 
quality of life
Impact of UDCA use on quality of life
Raszeja-
Wyszomirska et 
al 29
2015 Poland Quantitative Patients (n=205)
Healthy controls
Comparison of quality of life domains between 
patients and controls
Impact of patient and disease related factors on 
quality of life
Rishe et al 30 2008 USA Quantitative Patients (n=238) Experience of living with itch
Saich et al
*conference 
abstract only31
2015 USA Quantitative Patients (n=214) and 
physicians (n=322)
Comparison of patient perceptions of care versus 
physician perspectives
Continued
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Authorship
Publication 
date Location Methodology
Population (size of 
sample with PBC) Research question
Selmi et al 32 2007 USA Quantitative Patients (n=1032) Comparison of activity scores, symptoms and 
social life scores between patients and healthy 
controls
Sogolow et al 42 2010 USA Mixed methods Patients (n=100) Experience of stigma associated with diagnosis
Why do some women experience more stigma than 
others?
What impact does stigma have on quality of life?
Stanca et al 33 2005 USA Quantitative Patients (n=70) Impact of fatigue on quality of life
Untas et al 34 2015 France Quantitative Patients (n=130) Quality of life perception among women with PBC 
compared with a group of women with diabetes
Yagi et al
*conference 
abstract only35
2016 Japan Quantitative Patients (n=180) Comparison between patient and physician 
reported symptoms
Wong et al 36 2008 China Quantitative Patients (n=44) Comparison of symptoms scores, quality of life 
scores and depression scores between patients 
with PBC and two control groups (hypertension and 
chronic hepatitis B)
CBT, cognitive behavioural therapy; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid.
Table 1 Continued
Table 2 Comparison of primary biliary cholangitis and breast cancer
PBC Breast cancer
Gender F:M 9:1 (2) F:M 99:1 (40)
Age Most common in fifth and sixth decade2 50% over 6515
Prognosis 70% response rate6 >70% 5-year survival15
Long-term treatment required Yes, UDCA Some cases—hormonal treatment
Long-term symptoms Itch and fatigue Lymphoedema
PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.
methods were used in eight of the studies,45–52 five used 
qualitative methods53–58 and one mixed methods study58 
was identified. Nine studies looked at the views of the 
patient population,46–48 50 53–57 six included primary 
care clinicians46 48 49 55 57 58 and five included specialists 
(comprising surgeons, oncologists and nurses).45 51 52 55 56
Barriers to primary care follow-up identified included 
lack of knowledge among primary care physicians which 
was a recurrent theme among patients,50 53 54 57 special-
ists45 51 56 and primary care physicians themselves.49 57 58 
Allied to this concern was a fear that recurrence could 
be missed which was expressed by both primary care 
and specialist care55 with some primary care clinicians 
expressly mentioning medicolegal concerns.46 55 There 
was an association between cases where patients had 
experienced delays at the time of initial diagnosis and 
reduced confidence in their primary care practitioners 
ability to provide adequate follow-up.57 When asked to 
rate their survival outcomes in different healthcare 
settings, patients felt that their chance of survival long 
term was higher if they were followed up by a specialist.47
In terms of practical aspects of care, both patients and 
doctors felt that primary care clinicians are already over-
worked,46 49 53 that communication between primary care 
and specialists was poor54 55 and this may impact on care. 
Specialists highlighted that they would lose long-term 
outcome data if they did not follow-up patients them-
selves.45 They also described the relationship that forms 
with patients over time which was echoed by patients who 
described forming a bond with their specialists and feel-
ings of abandonment when discharged.54 55 The special-
ists reported the positive reinforcement they received 
from following up patients in remission rather than just 
seeing patients with complications and more advanced/
untreatable disease.55
dIscussIon
This scoping exercise identified the paucity of available 
literature exploring patient and HCP perspectives on 
the follow-up and management of PBC and a lack of any 
data around the role of primary care in the long-term 
management of patients with low-risk PBC. However, 
studies reporting stakeholder perspectives on changes to 
the delivery of breast cancer follow-up care have shown 
that not all patients or practitioners are comfortable with 
management being located substantially in the primary 
care setting. A series of themes emerged which have 
relevance to proposed care pathway changes including 
the knowledge base and workload of primary care, 
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Figure 2 Study selection process for breast cancer.
communication between care settings and the impor-
tance of the doctor–patient relationship. Within the data 
available specifically for PBC, the impact of delegitimi-
sation and stigmatisation felt by PBC patients is likely 
to be of relevance when developing new strategies for 
follow-up care.
This scoping review has identified a gap in the litera-
ture around patient and HCP perspectives on manage-
ment in primary care and the need for further study in 
this area to look specifically at the potential concerns 
of users of this pathway and whether or not the themes 
identified in this scoping review are relevant, if there are 
additional barriers or facilitators not identified here and, 
if so, how they can be overcome.
As is common with the use of a scoping review rather 
than a systematic review, there was a focus on identifying 
the breadth of literature available rather than looking 
at the available studies in depth and the quality of the 
studies identified was not assessed. However, the identi-
fication that there is little relevant literature in this field 
meant that this was less important. We aimed to conduct 
a comprehensive search of the literature, using a multiple 
database strategy. However, it is possible that some rele-
vant articles were missed. The lack of identification of 
additional relevant studies from reference lists of the 
chosen papers would support the belief that the search 
identified the relevant data in the field. Finally, it is not 
possible to know whether, and to what extent, any of the 
conditions considered by the authors for the second 
stage of the scoping study (including other forms of auto-
immune disease, other forms of chronic liver disease and 
breast cancer) truly act as comparators to PBC. While 
breast cancer was chosen as a comparator condition due 
to its similarities to PBC in terms of demographics of the 
patient population, this decision makes the assumption 
about the overall importance of patient demographics 
in determining its healthcare related behaviours. In 
addition, there are likely to be fundamental differences 
in comparing a malignant and non-malignant condition 
that will impact on how patients and clinicians view their 
future care needs. Finally, PBC as a rare disease is likely 
to pose different challenges to breast cancer which is now 
relatively common.
conclusIon
The recent guidelines from both the UK and European 
Societies propose a shift towards individualised care for 
patients with PBC. While individualised care is not explic-
itly defined, one potential consequence that is discussed 
in the British Guidelines is the discharge of patients 
deemed ‘low risk’ from hospital care to follow-up in 
primary care. The feasibility of this strategy is unclear and 
as such, the purpose of this scoping review was to identify 
the breadth and depth of the data already available about 
patient and clinician perspectives on management in 
primary care in order to identify facilitators and barriers 
to implementing this in practice. This review however 
highlighted that there is in fact a lack of data and that 
in order to be able to definitively answer the question of 
feasibility within PBC, further study may be required.
In developing a stratified approach to the care of the 
patient with PBC it will be essential to frame changes in 
care around high quality research. Underpinning this are 
opportunities to change practice by first of all an emphasis 
on education. This should address specific education for 
patients with PBC, and for primary care physicians, a 
broader education effort on the management of chronic 
liver diseases. With such an approach there would then 
be a greater opportunity to perhaps implement further 
change though targeted education, and use of smart 
technology/Apps to aid individualise risk assessment 
and changes to care pathways. Any approaches to change 
would require sensitive implementation adapted to local 
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Table 3 Summary of themes identified in breast cancer literature
Authorship
Publication 
date Location Methodology
Population 
(size of 
sample) Findings/themes identified
Adewuyi-Dalton 
et al 53
1998 UK Qualitative—face 
to face one on one 
interviews
Patients (n=109) GPs—overworked; lack specialist knowledge; 
specialist care less important over time as concern 
about recurrence lessens
Brennan et al 51 2010 Australia Quantitative—
questionnaire
Secondary care 
(n=217)
GPs need more training to follow-up patients
Brennan et al 54 2011 Australia Qualitative—
telephone interviews
Patients (n=20) Advantages GP care: convenience, reduced travel 
involved, take pressure off specialists
Disadvantages of GP care: poor communication 
between specialist and GP, GPs lack of knowledge, 
established relationship with specialist during 
treatment
Dawes et al 58 2015 USA Mixed methods—
questionnaire and 
focus group
Primary care
(Survey n=59
Focus group 
n=36+)
Favoured specialists to provide follow-up care
Lack of knowledge especially endocrine treatment
Donelly et al 45 2007 UK Quantitative—
questionnaire
Secondary care 
(n=256)
Advantages of GP care: reduced clinic workload
Disadvantages: lack of training, loss of outcome data
Kantsiper et al 55 2009 USA Qualitative—focus 
group
Patients (n=21)
Primary care 
(n=15)
Secondary care 
(n=160
Specialists are experts and GPs role is in referral not 
management. Feelings of abandonment on discharge
Fear of missing recurrence and medicolegal 
implications, not able to keep up to date with 
information, poor communication from specialists
Better at detecting recurrence and managing side 
effects than GPs, like following up survivors (positive 
experience), establish bond with patient
Kerrigan et al 46 2014 Ireland Quantitative Patients (n=87)
Primary care 
(n=53)
Supportive of GP care: able to explain breast cancer, 
able to perform examination, easy links to specialist 
if needed
Increased workload and costs, concern regarding 
medicolegal aspects of care
Kwast et al 56 2013 Netherlands Qualitative—face to 
face interviews
Patients (n=23)
Clinicians (n=18)
GP—role in psychosocial aspects of care; lacks 
specialist knowledge; too busy
GP care cheaper; lack specialist knowledge
Luker et al 57 2000 UK Qualitative—face 
to face/telephone 
interviews
Patients (n=67)
Primary care 
(n=31)
GP—lacks knowledge; delay in diagnosis associated 
with decreased confidence in follow-up
Difficult to keep up to date with new information, 
prognostication challenging
Mao et al 50 2009 USA Quantitative Patients (n=300) Holistic care through GP; psychosocial aspects 
of management; variable breast cancer specific 
knowledge
Mayer et al 47 2012 Canada Quantitative Patients (n=218) Specialist visit reduces anxiety and improves survival 
compared with primary care
Roorda et al 49 2013 Netherlands Quantitative—
questionnaires
Primary care 
(n=502)
40% of GPs happy to provide exclusive care 
after 5 years; barriers—patient preference, lack of 
knowledge, workload improving GP care improving 
GP care—active discharge from specialist care, 
written information, education, easy access back to 
specialist care if required
Smith et al 48 2015 Canada Quantitative Patients 
(n=1065)
Primary care 
(n=587)
Confident in GPs ability to screen for recurrence, less 
confident in GPs managing osteoporosis, hormonal 
treatment
Confident in screening for recurrence, lower 
confidence in lymphoedema, family counselling, 
psychosocial aspects
Van Hezewijk et 
al52
2011 Netherlands Quantitative—
questionnaire
Secondary care 
(n=130)
GPs should play a minor role in follow-up. Reasons 
not specified
GP, general practitioner.
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resources: for example, where large group practices and 
primary networks exist in primary care, opportunities to 
use a few embedded primary care liver champions may 
be effective, whereas in rural areas, IT/nurse supported 
change to care for GPs may be better.
Across the various models of healthcare delivery, it will 
be essential to evaluate feasibility of stratified care for 
patients with PBC in many different settings and health-
care models. Solutions for urban areas may, for example, 
be distinct to those for rural environments, and obstacles 
to implementation may include economic and personnel 
issues. Nevertheless, there exists the opportunity to be 
innovative in-service design and then to evaluate the 
impact of any service change.
We believe the similarities between the patient, disease 
and management characteristics of postsurgery breast 
cancer and low-risk PBC patients to be such that it is 
reasonable to anticipate comparable barriers will emerge 
to the implementation of the new management guide-
lines for PBC. Dedicated research involving patients 
and clinicians is still required to confirm that barriers to 
change exist, to identify what these barriers are and to 
plan strategies for intervention in this group of patients 
and clinicians. This information will be relevant not only 
to the possible future implementation of stratified care 
models in the PBC population but will also be applicable 
to other rare chronic diseases including, but not exclu-
sive to, liver disease.
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